Association between labetalol use for hypertension in pregnancy and adverse infant outcomes

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 175, Issue 1, 2014, Pages 124-128

  Xie, Ri Hua ^a,b,c   Guo, Yanfang ^b,c   Krewski, Daniel ^b,d   Mattison, Donald ^b,d   Walker, Mark C ^b,c   Nerenberg, Kara ^e   Wen, Shi Wu ^b,c,f  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF OTTAWA   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d RISK SCIENCES INTERNATIONAL   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Chronic hypertension; Hospitalization; Labetalol; Methyldopa; Pregnancy

Indexed keywords

LABETALOL; METHYLDOPA; ANTIHYPERTENSIVE AGENT;

ADULT; ADVERSE DRUG REACTION; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHILD DEATH; COHORT ANALYSIS; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; PREGNANCY OUTCOME; PREMATURITY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; RETROSPECTIVE STUDY; SEIZURE; SEPSIS; SIDE EFFECT; SMALL FOR DATE INFANT; STILLBIRTH; CHEMICALLY INDUCED; COMPARATIVE STUDY; HYPERTENSION, PREGNANCY-INDUCED; NEWBORN; NEWBORN DISEASE; PREGNANCY;

ADULT; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; LABETALOL; METHYLDOPA; PREGNANCY; RETROSPECTIVE STUDIES;

EID: 84898057248     PISSN: 03012115     EISSN: 18727654     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2014.01.019     Document Type: Article

References (25)

1. SOGC Hypertension and pregnancy guidelines J Obstet Gynaecol Can 30 2008 1 52
2. J. Zhang, J. Zeisker, and M.C. Hatch Epidemiology of pregnancy-induced hypertension Epidemiol Rev 19 1997 218 232
3. B.K. Wittmann, K.J. Murphy, J.F. King, B.H. Yuen, D. Shaw, and A.G. Wittman Maternal mortality in British Columbia in 1971-86 CMAJ 139 1988 37 40
4. National High Blood Pressure Education Working Group Report on high blood pressure in pregnancy Am J Obstet Gynecol 163 1990 1691 1712
5. L.A. Magee, E. Abalos, and P. von Dadelszen et al. How to manage hypertension in pregnancy effectively Br J Clin Pharmacol 72 2011 394 401
6. T. Podymow, and P. August Update on the use of antihypertensive drugs in pregnancy Hypertension 51 2008 960 969
7. E. Abalos, L. Duley, D.W. Steyn, and D.J. Henderson-Smart Antihypertensive drug therapy for mild to moderate hypertension during pregnancy Cochrane Database Syst Rev 1 2007 CD002252
8. ACOG Practice Bulletin Chronic hypertension in pregnancy Obstet Gynecol 119 2012 396 407
9. A.V. Chobanian, G.L. Bakris, and H.R. Black et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, and Treatment of high blood pressure. The Seventh Report of the Joint Committee JAMA 289 2003 2560 2572
10. L. Magee, M. Helewa, J.M. Moutquin, P. von Dadelszen, and Hypertension Guidelines Committee Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy JOGC 30 Suppl. 1 2008 S1 S48
11. L.A. Magee, and L. Duley Oral beta-blockers for mild to moderate hypertension during pregnancy Cochrane Database Syst Rev 3 2003 CD002863
12. A.M. El-Qarmalawi, A.H. Morsy, A. Al-Fadly, A. Obeid, and M. Hashem Labetalol vs. methydopa in the treatment of pregnancy-induced hypertension Int J Gynaecol Obstet 49 1995 125 130
13. K. Duckitt, and D. Harrington Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies BMJ 330 2005 565
14. M.S. Kramer, R.W. Platt, and S.W. Wen et al. A new and improved population-based Canadian reference of birth weight for gestational age Pediatrics 108 2 2001 e35
15. K. Karlsson, Y. Lundgren, and U. Ljungblad The acute effects of a non-selective beta-adrenergic blocking agent in hypertensive pregnant rats Acta Obstet Gynecol Scand Suppl 118 1984 81 84
16. I. Kjellmer, A. Dagbjartsson, A. Hrebk, K. Karlsson, and K.G. Rosen Maternal beta-adrenoceptor blockade reduces fetal tolerance to asphyxia. A study in pregnant sheep Acta Obstet Gynecol Scand Suppl 118 1984 75 80
17. D.D. Houlihan, M.C. Dennedy, N. Ravikumar, and J.J. Morrison Anti-hypertensive therapy and the feto-placental circulation: effects on umbilical artery resistance J Perinat Med 32 2004 315 319
18. S.N. Molvi, S. Mir, V.S. Rana, F. Jabeen, and A.R. Malik Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa Arch Gynecol Obstet 285 2012 1553 1562
19. S. Immanni, E.I. Khan, and M. Staunton Hypoglycaemia secondary to labetalol infusion J Coll Physicians Surg Pak 21 2011 297 298
20. K.Y. Heida, G.G. Zeeman, T.R. Van Veen, and C.V. Hulzebos Neonatal side effects of maternal labetalol treatment in severe preeclampsia Early Hum Dev 88 2012 503 507
21. Health databases in Saskatchewan L.M. Strand, W. Downey, and B.L. Strom Pharmacoepidemiology 2nd ed. 1994 John Wiley & Sons Chichester 217 230
22. S.L. West, A. Richter, C.A. Melfi, M. McNutt, M.E. Nennstiel, and J.A. Mauskopf Assessing the Saskatchewan database for outcomes research studies of depression and its treatment J Clin Epidemiol 53 2000 823 831
23. L.T. De Jong van den Berg, N. Feenstra, H.T. Sorensen, and M.C. Cornel Improvement of drug exposure data in a registration of congenital anomalies. Pilot study: pharmacist and mother as sources for drug exposure data during pregnancy Teratology 60 1999 33 36
24. K.J. Rothman, and S. Greenland Modern epidemiology 2nd ed. 1998 Lippincott Raven Philadelphia
25. R.H. Xie, Y. Guo, and D. Krewski et al. Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population Eur J Obstet Gynecol Reprod Biol 171 2013 281 285